Tislelizumab in Addition to BACE in Patients With NSCLC
Status:
Not yet recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
This is a single-arm phase II trial to determine the efficacy and safety of Tislelizumab in
addition to bronchial arterial chemoembolization in stage III-Ⅳ NSCLC patients who failed,
refused or ineligible to receive standard treatments.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University